| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA461: Roflumilast for treating chronic obstructive pulmonary disease (replaced TA244) |
|
Medicine details |
|
| Medicine name | roflumilast (Daxas®) |
| Formulation | 500 micrograms film-coated tablet |
| Reference number | 757 |
| Indication | Maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 postbronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/07/2010 |
| NICE guidance | TA461: Roflumilast for treating chronic obstructive pulmonary disease (replaced TA244) |